Starpharma's HIV Drug Fast Tracked By FDA
Posted on: Wednesday, 11 January 2006, 12:00 CST
The FDA has granted fast track status to Starpharma's VivaGel, an investigational new drug for the prevention of HIV.
VivaGel is currently being developed as a vaginal microbicide gel to prevent the transmission of genital herpes and HIV. VivaGel was also recently awarded $20 million by the US-based NIAID, a division of the National Institutes of Health (NIH) to accelerate its development.
Under the fast track program, portions of the new drug application can be submitted to the FDA before the application is completed. This early review shortens FDA approval times significantly.
"VivaGel's new drug application will receive priority review which has a shorter review time," commented John Raff, CEO of Starpharma. "Fast Track status also provides more opportunity for Starpharma to communicate with the FDA to ensure the success of the VivaGel development program."
With no cure currently available for HIV or genital herpes, and the limited success of existing prevention strategies, infection rates in the US and elsewhere are expected to continue to rise sharply.
Source: Datamonitor
Related Articles
- FDA Says New Pfizer HIV Drug Appears Safe
- FDA Report Supports Merck HIV Drug Approval
- Spectrum Pharmaceuticals Announces FDA's Oncology Drug Advisory Committee to Review Satraplatin for the Treatment of Hormone Refractory Prostate Cancer
- Progenics Reports Successful Early-Stage Trial for HIV Drug
- FDA Warns of HIV Drug Mix-Up
- Theratech says FDA OKs design of HIV drug trial
- Genta Announces FDA's Oncology Drug Advisory Committee Will Review Genasense(R) As Treatment for Chronic Lymphocytic Leukemia
- Progenics' HIV Drug Put on Fast Track
- Health: Generic HIV Drugs From India Pass Review By Health Body
- FDA Says Hoffmann-La Roche Made Misleading Claims About HIV Drug
 |
 |
User Comments (0)
RSS Feeds